Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of six systematic review(s)/meta-analysis(es). ^[1-6]
• Health-Related Quality of Life and Asthma Control: Fluticasone propionate/salmeterol (FP/Sal) improved health-related quality of life (HRQoL) with an AQLQ (Asthma Quality of Life Questionnaire) change from baseline (CFB) of 0.65 vs. placebo, 0.58 vs. LABA, 0.21 vs. ICS alone, 0.06 vs. other ICS/LABA, and 0.00 vs. ICS/formoterol MART. These HRQoL improvements were strongly correlated with Asthma Control Questionnaire (ACQ) scores (R = 0.94).
• Asthma Exacerbation and Control in Children: Salmeterol/fluticasone (SFC) in children and adolescents (4-18 years) was associated with a lower risk of asthma exacerbation, improved peak expiratory flow (PEF)%pred, asthma control levels, and better scores on the childhood asthma control test compared to montelukast and the montelukast/fluticasone combination (MFC).
• Comparison with Formoterol/Budesonide (FB): The FB pressurized metered-dose inhaler (pMDI) showed benefits in lung function, asthma control, and reduced symptoms and exacerbations for patients aged 6 years and older, indicating effective management in pediatric asthma.
• General Safety Profile: Fluticasone propionate/salmeterol (FP/Sal) showed no significant increase in adverse events compared to other treatments, with similar safety profiles observed between formoterol/budesonide and salmeterol/fluticasone combinations, including no significant differences in mortality or non-fatal serious adverse events.
• Pediatric Safety: In children and adolescents, salmeterol/fluticasone (SFC) and montelukast/fluticasone (MFC) showed comparable safety profiles, with no significant differences in adverse events. Additionally, fluticasone propionate/formoterol (FP/FORM) in pediatric patients had a lower incidence of nasopharyngitis compared to FP/Sal.
• Population Types and Subgroup Considerations: In moderate-to-severe asthma patients, fluticasone propionate/salmeterol (FP/Sal) was effective in improving HRQoL and asthma control. For children and adolescents aged 4-18 years, salmeterol/fluticasone (SFC) showed greater benefits in asthma control and reduced exacerbations compared to montelukast and montelukast/fluticasone (MFC). Among pediatric patients aged 6 and older, the formoterol/budesonide (FB) pressurized metered-dose inhaler (pMDI) demonstrated improved long-term asthma management outcomes.